A Pan-Inhibitor of Phosphate Transporters AP306 in Hemodialysis Patients.
作者信息
Kowalczyk Nicholas S, Sprague Stuart M
机构信息
Department of Medicine, University of Chicago, Chicago, Illinois, USA.
Norman M. Simon MD Division of Nephrology and Hypertension, Endeavor Health Medical Group, Evanston, Illinois, USA.
出版信息
Kidney Int Rep. 2025 Mar 14;10(5):1318-1320. doi: 10.1016/j.ekir.2025.03.011. eCollection 2025 May.
Abstract
摘要
相似文献
1
A Pan-Inhibitor of Phosphate Transporters AP306 in Hemodialysis Patients.血液透析患者中磷酸盐转运体AP306的泛抑制剂
Kidney Int Rep. 2025 Mar 14;10(5):1318-1320. doi: 10.1016/j.ekir.2025.03.011. eCollection 2025 May.
2
A Pan-Inhibitor of Phosphate Transporters AP306 in Hemodialysis Patients.血液透析患者中磷酸盐转运体AP306的泛抑制剂
Kidney Int Rep. 2025 Feb 3;10(4):1143-1151. doi: 10.1016/j.ekir.2025.01.038. eCollection 2025 Apr.
3
EOS789, a broad-spectrum inhibitor of phosphate transport, is safe with an indication of efficacy in a phase 1b randomized crossover trial in hemodialysis patients.EOS789 是一种广谱磷酸盐转运抑制剂，在血液透析患者的 1b 期随机交叉试验中显示出疗效和安全性。
Kidney Int. 2021 May;99(5):1225-1233. doi: 10.1016/j.kint.2020.09.035. Epub 2020 Oct 31.
4
Anaphylactoid reactions during hemodialysis in sheep are ACE inhibitor dose-dependent and mediated by bradykinin.绵羊血液透析期间的类过敏反应呈血管紧张素转换酶抑制剂剂量依赖性，并由缓激肽介导。
Kidney Int. 1998 Apr;53(4):1026-35. doi: 10.1111/j.1523-1755.1998.00837.x.
5
EOS789, a novel pan-phosphate transporter inhibitor, is effective for the treatment of chronic kidney disease-mineral bone disorder.EOS789是一种新型的泛磷酸盐转运体抑制剂，对治疗慢性肾脏病-矿物质和骨异常有效。
Kidney Int. 2020 Aug;98(2):343-354. doi: 10.1016/j.kint.2020.02.040. Epub 2020 Apr 23.
6
7
Kinin generation by hemodialysis membranes as a possible cause of anaphylactoid reactions.血液透析膜产生激肽作为类过敏反应的一个可能原因。
Braz J Med Biol Res. 1994 Aug;27(8):1975-83.
8
Studies on the ability of hemodialysis membranes to induce, bind, and clear human interleukin-1.关于血液透析膜诱导、结合和清除人白细胞介素-1能力的研究。
J Lab Clin Med. 1988 Jul;112(1):76-86.
9
Effects of EOS789, a novel pan-phosphate transporter inhibitor, on phosphate metabolism : Comparison with a conventional phosphate binder.新型全磷酸盐转运体抑制剂 EOS789 对磷酸盐代谢的影响：与传统磷酸盐结合剂的比较。
J Med Invest. 2023;70(1.2):260-270. doi: 10.2152/jmi.70.260.
10
Influence of the use of phosphate binders on serum levels of calcium phosphate in patients with chronic kidney disease undergoing hemodialysis: A retrospective and prospective study.在接受血液透析的慢性肾脏病患者中，使用磷酸盐结合剂对血清钙磷水平的影响：一项回顾性和前瞻性研究。
Saudi Pharm J. 2014 Sep;22(4):333-7. doi: 10.1016/j.jsps.2013.08.004. Epub 2013 Sep 14.
本文引用的文献
1
A Pan-Inhibitor of Phosphate Transporters AP306 in Hemodialysis Patients.血液透析患者中磷酸盐转运体AP306的泛抑制剂
Kidney Int Rep. 2025 Feb 3;10(4):1143-1151. doi: 10.1016/j.ekir.2025.01.038. eCollection 2025 Apr.
2
Tenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE Study.替班那诺治疗维持性透析患者高磷血症的疗效：来自 OPTIMIZE 研究的结果。
Kidney360. 2024 May 1;5(5):732-742. doi: 10.34067/KID.0000000000000387. Epub 2024 Feb 7.
3
Tenapanor Improves Long-Term Control of Hyperphosphatemia in Patients Receiving Maintenance Dialysis: the NORMALIZE Study.替班那诺改善维持性透析患者高磷血症的长期控制：NORMALIZE 研究。
Kidney360. 2023 Nov 1;4(11):1580-1589. doi: 10.34067/KID.0000000000000280. Epub 2023 Oct 19.
4
The basics of phosphate metabolism.磷酸盐代谢基础。
Nephrol Dial Transplant. 2024 Jan 31;39(2):190-201. doi: 10.1093/ndt/gfad188.
5
Serum Phosphorus Level Rises in US Hemodialysis Patients Over the Past Decade: A DOPPS Special Report.过去十年美国血液透析患者血清磷水平上升：一项DOPPS特别报告。
Kidney Med. 2022 Dec 14;5(2):100584. doi: 10.1016/j.xkme.2022.100584. eCollection 2023 Feb.
6
Mineral Bone Disorders in Kidney Disease Patients: The Ever-Current Topic.肾脏病患者的矿物质和骨代谢紊乱：永恒的话题。
Int J Mol Sci. 2022 Oct 13;23(20):12223. doi: 10.3390/ijms232012223.
7
Past, Present, and Future of Phosphate Management.磷酸盐管理的过去、现在与未来
Kidney Int Rep. 2022 Feb 1;7(4):688-698. doi: 10.1016/j.ekir.2022.01.1055. eCollection 2022 Apr.
8
KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).KDIGO 2017慢性肾脏病-矿物质和骨异常（CKD-MBD）诊断、评估、预防及治疗临床实践指南更新
Kidney Int Suppl (2011). 2017 Jul;7(1):1-59. doi: 10.1016/j.kisu.2017.04.001. Epub 2017 Jun 21.
9
Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients.维持性透析患者的药丸负担、依从性、高磷血症及生活质量
Clin J Am Soc Nephrol. 2009 Jun;4(6):1089-96. doi: 10.2215/CJN.00290109. Epub 2009 May 7.
Zotero 插件